Robert Paul
Cardiovascular Disease · West Des Moines, IANPI 1386626109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 8.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,416 and has fallen 97.0% since, to $193 in 2021. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $57.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$709
- Boehringer Ingelheim$696
- AstraZeneca$642
- Novo Nordisk$603
- Lantheus Medical Imaging, Inc.$578
- Amgen$443
- plus $5K from 33 others
What the payments were for
- Food & beverage$8,65599%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $709 |
| Boehringer Ingelheim | 8 | $696 |
| AstraZeneca | 11 | $642 |
| Novo Nordisk | 12 | $603 |
| Lantheus Medical Imaging, Inc. | 8 | $578 |
| Amgen | 8 | $443 |
| Inari Medical, Inc. | 8 | $425 |
| Pfizer | 7 | $424 |
| Novartis | 9 | $359 |
| Tactile Systems Technology Inc | 4 | $260 |
| Smith+Nephew | 3 | $257 |
| Actelion Pharmaceuticals US, Inc. | 3 | $228 |
| Sanofi-aventis U.S. LLC | 5 | $216 |
| GSK | 2 | $213 |
| Amarin Pharma, Inc. | 10 | $198 |
| Medicure Pharma Inc. | 2 | $182 |
| E.r. Squibb & Sons, L.L.C. | 9 | $170 |
| Merck | 2 | $142 |
| Chiesi USA, Inc. | 1 | $138 |
| Regeneron Healthcare Solutions, Inc. | 3 | $130 |
| Lundbeck LLC | 3 | $126 |
| Portola Pharmaceuticals, LLC | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Bristol Myers Squibb | 1 | $125 |
| Osiris Therapeutics Inc. | 1 | $122 |
| Abbott | 1 | $118 |
| Boston Scientific | 1 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $114 |
| Biocompatibles, Inc. | 1 | $110 |
| AbbVie | 1 | $100 |
| Astellas Pharma US Inc | 1 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $87 |
| Novocure Inc. | 1 | $79 |
| Organogenesis Inc. | 1 | $78 |
| Alnylam Pharmaceuticals Inc. | 1 | $65 |
| Zimmer Biomet | 1 | $61 |
| Jazz Pharmaceuticals Inc. | 1 | $52 |
| Lilly USA, LLC | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,753 in reported general payments places this provider in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in West Des Moines
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Suzanne FeigofskyWest Des Moines$59K
- Lucas GrobenWest Des Moines$6K
- Krishna Theja ReddyWest Des Moines$5K
- Randolph RoughWest Des Moines$3K
- Paul WesleyWest Des Moines$2K
- Brian OlshanskyIowa City$219K
- Gursukhman Deep SidhuDavenport$60K
- Tyler RasmussenCedar Rapids$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.